Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510260, China.
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
BMC Cancer. 2024 Aug 6;24(1):963. doi: 10.1186/s12885-024-12735-3.
The aim of this study was to investigate the incidence and risk factors of new-onset hypopituitarism after gamma knife radiosurgery (GKRS) for pituitary adenomas in a single center.
In this retrospective study, 241 pituitary adenoma patients who underwent GKRS from 1993 to 2016 were enrolled. These patients had complete endocrine, imaging, and clinical data before and after GKRS. The median follow-up time was 56.0 (range, 12.7-297.6) months.
Fifty patients (20.7%) developed new-onset hypopituitarism after GKRS, including hypogonadism (n = 22), hypothyroidism (n = 29), hypocortisolism (n = 20), and growth hormone deficiency (n = 4). The median time to new-onset hypopituitarism was 44.1 (range, 13.5-141.4) months. The rates of new-onset hypopituitarism were 7%, 16%, 20%, 39%, and 45% at 1, 3, 5, 10, and 15 years, respectively. For those patients treated with a single GKRS, sex (p = 0.012), suprasellar extension (p = 0.048), tumor volume (≥ 5 cm) (p < 0.001), tumor progression (p = 0.001), pre-existing hypopituitarism (p = 0.011), and previous surgery (p = 0.009) were significantly associated with new-onset hypopituitarism in univariate analysis. In the multivariate analysis, tumor volume (≥ 5 cm) and tumor progression were associated with new-onset hypopituitarism (hazard ratio [HR] = 3.401, 95% confidence interval [CI] = 1.708-6.773, p < 0.001 and HR = 3.594, 95% CI = 1.032-12.516, p = 0.045, respectively). For patients who received 2 or more times GKRS, no risk factors associated with new-onset hypopituitarism were found.
New-onset hypopituitarism was not uncommon after GKRS for pituitary adenomas. In this study, large tumor volume (≥ 5 cm) and tumor progression were associated with new-onset hypopituitarism after a single GKRS.
本研究旨在探讨单中心伽玛刀放射外科(GKRS)治疗垂体腺瘤后新发垂体功能减退症的发生率和危险因素。
在这项回顾性研究中,共纳入了 1993 年至 2016 年间接受 GKRS 的 241 例垂体腺瘤患者。这些患者在 GKRS 前后均有完整的内分泌、影像学和临床资料。中位随访时间为 56.0(范围,12.7-297.6)个月。
50 例(20.7%)患者在 GKRS 后发生新发垂体功能减退症,包括性腺功能减退症(n=22)、甲状腺功能减退症(n=29)、皮质醇功能减退症(n=20)和生长激素缺乏症(n=4)。新发垂体功能减退症的中位时间为 44.1(范围,13.5-141.4)个月。1、3、5、10 和 15 年时的新发垂体功能减退症发生率分别为 7%、16%、20%、39%和 45%。对于接受单次 GKRS 治疗的患者,性别(p=0.012)、鞍上扩展(p=0.048)、肿瘤体积(≥5cm)(p<0.001)、肿瘤进展(p=0.001)、术前垂体功能减退症(p=0.011)和既往手术(p=0.009)与单因素分析中的新发垂体功能减退症显著相关。多因素分析显示,肿瘤体积(≥5cm)和肿瘤进展与新发垂体功能减退症相关(风险比[HR]=3.401,95%置信区间[CI]1.708-6.773,p<0.001;HR=3.594,95%CI 1.032-12.516,p=0.045)。对于接受 2 次或以上 GKRS 治疗的患者,未发现与新发垂体功能减退症相关的危险因素。
GKRS 治疗垂体腺瘤后新发垂体功能减退症并不少见。在本研究中,单次 GKRS 后,大肿瘤体积(≥5cm)和肿瘤进展与新发垂体功能减退症相关。